ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.00 Consensus PT from Brokerages

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $38.00.

A number of equities analysts have recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th.

ABIVAX Société Anonyme Stock Up 6.8 %

ABVX opened at $5.97 on Tuesday. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $16.63. The company has a 50 day moving average of $6.71 and a 200 day moving average of $7.89.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ABVX. GAMMA Investing LLC increased its stake in ABIVAX Société Anonyme by 373.6% in the first quarter. GAMMA Investing LLC now owns 18,831 shares of the company’s stock valued at $118,000 after acquiring an additional 14,855 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at about $144,000. Stonepine Capital Management LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter worth approximately $110,000. Shay Capital LLC purchased a new stake in ABIVAX Société Anonyme in the fourth quarter worth approximately $366,000. Finally, Millennium Management LLC grew its position in ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after acquiring an additional 285,542 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.